Independent and joint effects of genomic and exposomic loads for schizophrenia on psychotic experiences in adolescents of European ancestry
This study aimed to assess the independent and joint associations of genomic and exposomic liabilities for schizophrenia with distressing psychotic experiences (PEs) and their persistence in early adolescence. The Adolescent Brain and Cognitive Development Study data from children with European ancestry were used (N = 5122). The primary outcome was past-month distressing PEs at the 3-year follow-up. Secondary outcomes were distressing PEs at varying cutoffs of persistence. Multilevel logistic regression models were used to test the associations of binary modes (>75th percentile) of polygenic risk score for schizophrenia (PRS-SCZ<sub>75</sub>) and exposome score for schizophrenia (ES-SCZ<sub>75</sub>) on the outcomes. Relative excess risk due to interaction (RERI) calculation indicated additive interaction. When analyzed independently, PRS-SCZ<sub>75</sub> was not significantly associated with past-month distressing PEs but with lifetime (OR 1.29 [95% CI 1.08, 1.53]) and repeating distressing PEs ≥2 waves (OR 1.34 [95% CI 1.08, 1.65]); whereas, ES-SCZ<sub>75</sub> was consistently associated with all outcomes, with increasing strength of association as a function of PEs persistence (one wave: OR 2.77 [95% CI 2.31, 3.31]; two waves: OR 3.16 [95% CI 2.54, 3.93]; three waves: OR 3.93 [95% CI 2.86, 5.40]; four waves: OR 3.65 [95% CI 2.34, 5.70]). When considered jointly, ES-SCZ<sub>75</sub> and PRS-SCZ<sub>75</sub> did not additively interact to predict past-month distressing PEs but showed significant additive interactions for lifetime (RERI = 1.26 [95%CI 0.14, 2.38]) and repeating distressing PEs ≥2 waves (RERI = 1.79 [95%CI 0.35, 3.23]). Genomic and exposomic liabilities for schizophrenia were independently and jointly associated with distressing PEs and their persistence in early adolescence.
Authors
- Andrea Fiorillo (ORCID: https://orcid.org/0000-0002-6926-0762)
- Angelo Arias-Magnasco (ORCID: https://orcid.org/0009-0000-0989-9049)
- Jim van Os (ORCID: https://orcid.org/0000-0002-7245-1586)
- Bart P. F. Rutten (ORCID: https://orcid.org/0000-0002-9834-6346)
- Gaia Sampogna (ORCID: https://orcid.org/0000-0002-9547-2793)
- Thanavadee Prachason (ORCID: https://orcid.org/0000-0002-9841-9488)
- Lotta-Katrin Pries (ORCID: https://orcid.org/0000-0003-3823-4155)
- Ran Barzilay (ORCID: https://orcid.org/0000-0002-3247-2331)
- Bochao Danae Lin (ORCID: https://orcid.org/0000-0002-4161-8021)
- Matteo Di Vincenzo
- Sinan Gülöksüz (ORCID: https://orcid.org/0000-0002-6626-1874)
Institutions
- Children's Hospital of Philadelphia (US)
- King's College London (GB)
- Utrecht University (NL)
- University of Campania "Luigi Vanvitelli" (IT)
- Mahidol University (TH)
- Maastricht University Medical Centre (NL)
- University Medical Center Utrecht (NL)
- Yale University (US)
- Maastricht University (NL)
- Ramathibodi Hospital (TH)
- University of Pennsylvania Health System (US)
- Lifespan (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Schizophrenia
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1038/s41537-025-00569-2
- Citations
- 4
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.31
Funders
- European Commission
- ZonMw
- National Institutes of Health
- HORIZON EUROPE Framework Programme
- National Institute of Mental Health